Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial)
Authors:
Open Access
- 5 May 2023
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-10
Abstract
Background: Distressing nightmares are a core symptom of posttraumatic stress disorder (PTSD) and contribute to psychiatric comorbidity, impaired physical health and decreased social functioning. No specific pharmacological treatment for PTSD-related nightmares is yet approved. Preliminary clinical data indicate that cannabinoid agonists can improve nightmares and overall PTSD symptoms in patients with PTSD. The primary objective of the study is to examine the efficacy of oral dronabinol (BX-1) versus placebo in reducing nightmares in patients with PTSD. The secondary objectives of the study are to examine the efficacy of oral BX-1 in reducing other PTSD symptoms. Methods: The study is designed as a multi-centric, double-blind, randomized (1:1), placebo-controlled, parallel group interventional trial. Eligible patients will be randomized to BX-1 or placebo, receiving a once-daily oral dose before bedtime for 10 weeks. Primary efficacy endpoint is the Clinician-Administered PTSD Scale (CAPS-IV) B2 score for the last week, measuring frequency and intensity of nightmares. Secondary efficacy endpoints are other disorder-specific symptoms in patients with PTSD. Further, tolerability and safety of dronabinol will be assessed. Discussion: This randomized controlled trial will provide evidence whether treating patients with PTSD and nightmares with dronabinol is safe and efficacious. Trial registration: NCT04448808, EudraCT 2019–002211-25.Keywords
All Related Versions
Funding Information
- Charité - Universitätsmedizin Berlin
This publication has 23 references indexed in Scilit:
- Randomized controlled trials of psychological and pharmacological treatments for nightmares: A meta-analysisSleep Medicine Reviews, 2013
- SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical TrialsAnnals of Internal Medicine, 2013
- Medical Comorbidity of Full and Partial Posttraumatic Stress Disorder in US AdultsPsychosomatic Medicine, 2011
- Relationship Between Household Income and Mental DisordersArchives of General Psychiatry, 2011
- Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: Results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related ConditionsJournal of Anxiety Disorders, 2011
- Evidence‐based treatments for PTSD, new directions, and special challengesAnnals of the New York Academy of Sciences, 2010
- The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)CNS Neuroscience & Therapeutics, 2009
- Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event‐exposed marijuana usersJournal of Traumatic Stress, 2007
- A Parallel Group Placebo Controlled Study of Prazosin for Trauma Nightmares and Sleep Disturbance in Combat Veterans with Post-Traumatic Stress DisorderBiological Psychiatry, 2007
- The development of a clinician‐administered PTSD scaleJournal of Traumatic Stress, 1995